EXCLUSIVE COLLABORATION WITH INTAS PHARMACEUTICALS

Arecor Therapeutics plc

("Arecor" or the "Group")

EXCLUSIVE FORMULATION COLLABORATION WITH INTAS PHARMACEUTICALS LTD

Cambridge, UK, 07 September 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd ("Intas").

Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated product for Intas.  The new product formulation supports improved usability for the patient compared to current marketed products and in particular facilitates home use outside of a healthcare environment.  Intas will fund the development work and has the option to acquire the global rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model (with associated potential milestone and royalty payments) to further develop and commercialise the product. Accord Healthcare, an affiliate of Intas, will, upon successful completion, promote this product across all major markets.

Arestat™ is an innovative and proprietary formulation technology platform which enhances the properties of therapeutic proteins, peptides and vaccines.  Arecor applies the Arestat™ technology to deliver superior reformulations of existing products as well as improving properties of new products in development.

Sarah Howell, Chief Executive Officer of Arecor, said:  "We are delighted to be working with Intas.  Our Arestat™ technology has the potential to deliver to Intas a new formulation to support development of a stable liquid product that meets patient needs.  This collaboration recognises our capabilities in product formulation, overcoming the complex challenges associated with developing these products.  Intas who are a new development partner for Arecor, further strengthens our portfolio with major pharmaceutical companies and demonstrates how our formulation expertise can bring enhanced products to market for partners that simplify care and improve medicine management."

"The collaboration with Arecor demonstrates our emphasis on value addition towards strengthening our portfolio to provide improved therapeutic options for patients and healthcare in general", said Mr. Binish Chudgar, Vice Chairman of Intas Pharmaceuticals.  "We are committed to improving access to innovation-driven value-added medicines to make a real difference in patient's life".

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

About Intas

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. Intas has more than 16,000 employees, sells products in more than 85 countries and has 14 manufacturing sites worldwide. The Intas group's revenues amounted to USD 2.1 bn in FY 2020 and the compounded annual growth rate of Intas' revenues has exceeded 25% in the past 10 years.

For more information, please visit www.intaspharma.com